Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bolt Biotherapeutics Inc (BOLT)

Bolt Biotherapeutics Inc (BOLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,754
  • Shares Outstanding, K 38,128
  • Annual Sales, $ 7,880 K
  • Annual Income, $ -69,200 K
  • 60-Month Beta 0.99
  • Price/Sales 5.81
  • Price/Cash Flow N/A
  • Price/Book 0.40
Trade BOLT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.51
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -0.57
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1001 +2.72%
on 03/18/24
1.5600 -27.56%
on 04/01/24
+0.0200 (+1.80%)
since 03/15/24
3-Month
1.0000 +13.00%
on 02/08/24
1.5600 -27.56%
on 04/01/24
-0.0200 (-1.74%)
since 01/12/24
52-Week
0.8400 +34.52%
on 12/01/23
2.0300 -44.33%
on 05/23/23
-0.3300 (-22.60%)
since 04/14/23

Most Recent Stories

More News
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 11.11% and 30.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

DNA : 0.9500 (-5.94%)
BOLT : 1.1300 (-5.83%)
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

PLRX : 13.55 (-4.24%)
BOLT : 1.1300 (-5.83%)
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?

Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHVN : 44.77 (-15.66%)
BOLT : 1.1300 (-5.83%)
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer

Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.

REGN : 898.56 (-0.68%)
SNY : 46.24 (+0.67%)
DVAX : 11.69 (-1.27%)
BOLT : 1.1300 (-5.83%)
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

NVS : 94.41 (+0.95%)
DVAX : 11.69 (-1.27%)
PBYI : 5.35 (+1.52%)
BOLT : 1.1300 (-5.83%)
Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review

Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.

GSK : 40.50 (-0.39%)
DVAX : 11.69 (-1.27%)
GILD : 67.75 (-0.47%)
BOLT : 1.1300 (-5.83%)
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv

Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.

NVS : 94.41 (+0.95%)
DVAX : 11.69 (-1.27%)
CYTK : 68.00 (-4.97%)
BOLT : 1.1300 (-5.83%)
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

DVAX : 11.69 (-1.27%)
LLY : 750.77 (-0.12%)
RIGL : 1.1500 (-4.17%)
BOLT : 1.1300 (-5.83%)
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

GSK : 40.50 (-0.39%)
NVS : 94.41 (+0.95%)
GILD : 67.75 (-0.47%)
BOLT : 1.1300 (-5.83%)
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract

VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.

GSK : 40.50 (-0.39%)
DVAX : 11.69 (-1.27%)
VIR : 8.57 (-4.46%)
BOLT : 1.1300 (-5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

See More

Key Turning Points

3rd Resistance Point 1.2600
2nd Resistance Point 1.2300
1st Resistance Point 1.1800
Last Price 1.1300
1st Support Level 1.1000
2nd Support Level 1.0700
3rd Support Level 1.0200

See More

52-Week High 2.0300
Fibonacci 61.8% 1.5754
Fibonacci 50% 1.4350
Fibonacci 38.2% 1.2946
Last Price 1.1300
52-Week Low 0.8400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar